Novel chemotherapeutic agents in colorectal cancer

European Journal of Surgical Oncology

Volumn 26, Issue 6, 2000, Pages 605-610

  Napier, M P ^a   Ledermann, J A ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Capecitabine; Chemotherapy; Colorectal cancer; Irinotecan; Oxaliplatin; Thymidylate synthase

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; 5 ETHYNYLURACIL; ANTINEOPLASTIC AGENT; CAPECITABINE; CYTOTOXIC AGENT; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; IRINOTECAN; NOLATREXED; ORZEL; OXALIPLATIN; PEMETREXED; PLEVITREXED; RALTITREXED; UFT;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CLINICAL TRIAL; COLORECTAL CANCER; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG TOLERABILITY; FOLATE METABOLISM; HUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL;

EID: 0033783711     PISSN: 07487983     EISSN: None     Source Type: Journal    
DOI: 10.1053/ejso.2000.0955     Document Type: Article

References (54)

1. Comparison of plasma and tissue levels of ZD1694 (Tomudex), a highly polyglutamatable quinazoline thymidylate synthase inhibitor, in pre-clinical models
2. ZD1694: A novel thymidylate synthase inhibitor with substantial activity in the treatment of patients with advanced colorectal cancer
3. Final results of a randomised trial comparing Tomudex (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer
4. Advanced colorectal cancer: Results from the latest raltitrexed (Tomudex) comparative study
5. Preliminary results of a multicenter randomised trial comparing 3 chemotherapy regimens (de Gramont, Lokich and Raltitrexed) in metastatic colorectal cancer
6. Interim results of a phase I trial suggest that Tomudex (Raltitrexed) may act synergistically with 5-fluorouracil in patients with advanced colorectal cancer
7. Tomudex (Raltitrexed) as a radiosensitizer: In vivo and in vitro results
8. A phase I study of Tomudex (Raltitrexed) with radiotherapy in patients with operable rectal cancer
9. Chemoradiation with raltitrexed (Tomudex) and concomitant preoperative radiotherapy has potential in the treatment of stage II/III resectable rectal cancer
10. Phase II study of a multi-targeted antifolate (LY231514) as first-line therapy in patients with locally advanced or metastatic colorectal cancer
11. A Phase II trial of LY231514 in patients with metastatic colorectal cancer
12. Initial phase I evaluation of the novel thymidylate synthase inhibitor, LY231514, using the modified continual reassessment method for dose escalation
13. A phase I clinical study of the novel antifolate AG337 given by a 5 day continuous infusion
14. Phase I and pharmacokinetic (PK) study of the non-polyglutamated thymidilate synthase (TS) inhibitor ZD9331 given as a 30 minute infusion every 3 weeks
15. A review of GERCOD trials of bimonthly leucovorin plus 5-fluorouracil 48-hour continuous infusion in advanced colorectal cancer: Evolution of a regimen
16. A prospective randomized comparison of continuous infusion fluorouracil with conventional bolus schedule in metastatic colorectal carcinoma: A mid Atlantic Oncology program study
17. A phase II study of weekly 24-hour infusion with high-dose fluorouracil with leucovorin in colorectal cancer
18. Fluorouracil in colorectal cancer a tale of two drugs: Implications for biochemical modulation
19. Capecitabine: An orally available fluoropyrimidine with tumor selective activity
20. Xeloda (capecitabine): An orally available tumor-selective fluoro-pyrimidine carbamate
21. Xeloda (capecitabine), a new oral fluoropyrimidine carbamate with an improved efficacy profile over other fluoropyrimidines
22. A phase I study of intermittent twice daily oral therapy with capecitabine in patients with advanced and/or metastatic solid cancer
23. Tumor selectivity of Xeloda in colorectal cancer patients
24. A randomized phase II study of Xeloda (capecitabine) in patients with advanced colorectal cancers
25. A phase III trial of Xeloda (Capecitabine) in previously untreated advanced/metastatic colorectal cancer
26. Phase II trial of uracil and tegafar plus oral leucovorin: An effective oral regimen in the treatment of metastatic colorectal carcinoma
27. Efficacy of oral Tegafur modulation by uracil and leucovorin in advanced colorectal cancer. A phase II study
28. Multicenter phase III trial of 5-fluorouracil or UFT in combination with folinic acid in patients with metastatic colorectal cancer
29. Oral fluoropyrimidines in the treatment of colorectal cancer
30. Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur 0.4M gimestat 1 M otostat potassium) in advanced gastric cancer patients
31. A phase II trial of seven day regimen of oral 776C85 plus a five day regimen of oral 5-fluorouracil in untreated patients with metastatic colorectal cancer: A North Central Cancer Treatment Group study
32. A phase II open-label study to evaluate a 28 day regimen of oral 5-fluorouracil plus 776C85 for the treatment of patients with previously untreated metastatic colorectal cancer
33. The role of DNA mismatch repair in platinum drug resistance
34. Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: A phase II multicenter study
35. Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines
36. A multicenter phase II trial of chemotherapy with oxaliplatin, 5 fluorouracil and folinic acid in patients with previously untreated metastatic colorectal cancer
37. A randomised trial of leucovorin and 5 fluorouracil with or without oxaliplatin in advanced colorectal cancer
38. Quality of life in advanced colorectal cancer: A comparison of quality of life during bolus plus infusion 5FU/leuvorin with or without oxaliplatin
39. Oxaliplatin with high dose leucovorin and fluorouracil 48 hour continuous infusion in pretreated metastatic colorectal cancer
40. Oxaliplatin and irinotecan (CPT11) phase I/II studies: Results in 5FU refractory colorectal cancer patients
41. Long-term survival of patients with unresectable colorectal livir metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery
42. Irinotecan is an active agent in untreated patients with metastatic colorectal cancer
43. Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer
44. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy naive patients and patients pretreated with fluorouracil-based chemotherapy
45. Phase II trial of irinotecan in patients with metastatic colorectal carcinoma
46. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer
47. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer
48. Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer
49. Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors
50. Bi-monthly CPT11 with leucovorin and 5-fluorouracil in pre-treated metastatic colorectal cancer
51. Phase I study of a weekly schedule of irinotecan, high dose folinic acid and 5-fluorouracil as first line chemotherapy in metastatic colorectal cancer: Final results
52. Weekly irinotecan, leucovorin and fluorouracil is superior to daily x 5 LV/FU in patients with previously untreated metastatic colorectal cancer
53. Irinotecan combined with fluorouracil compared with fluorouracil alone as first line treatment for metastatic colorectal cancer: A multicentre randomised trial
54. A prospective randomised trial of protracted venous infusion 5-flaorouracil with or without mitomycin C in advanced colorectal cancer